摘要
目的观察奥美拉唑、左氧氟沙星及克拉霉素新三联治疗十二指肠溃疡幽门螺杆菌(Helicobacter pylori,Hp)再感染复发的临床疗效。方法将52例十二指肠溃疡Hp再感染复发患者随机分成两组。治疗组26例为奥美拉唑新三联疗法,即口服奥美拉唑20mg、左氧氟沙星200mg及克拉霉素500mg,均为2次/日,连服1周。对照组26例为奥美拉唑四联疗法,即口服奥美拉唑20mg、丽珠得乐220mg、阿莫西林1000mg及甲硝唑400mg,均为2次/日,连服1周,1周后两组继续服用奥美拉唑20mg,2次/日,连服4周,各组疗程结束后一个月复查胃镜。结果51例病人完成治疗及随访,对照组有1例失访。奥美拉唑新三联组与四联组疗法Hp再感染根除率分别为92.3%(24/26)、84.0%(21/25),溃疡愈合率分别为96.2%(25/26)、92.0%(23/25),副反应发生率分别为11.5%(3/26)、32.0%(8/25),差异均无显著性(P>0.05)。Hp根除组溃疡愈合率(100.0%)明显高于Hp未根除组(72.7%),差异有显著性(P<0.001)。结论奥美拉唑新三联组有较理想的Hp再感染根除率及溃疡愈合率,且副反应发生率低;奥美拉唑新三联疗法可作为根除十二指肠溃疡Hp再感染复发的一线治疗或失败后的补救治疗方案。
Objective To observe the effects of omeprazole （Ome） plus levofloxacin plus Clarithromycin （OVC） in the treatment of Helicoibacter pylori （H pylori） reinfection in patients with duodenal ulcer（DU）. Methods Fifty-two patients with DU, who were confirmed by endoscopy with H pylori reinfection （confirmed by ^14C-UBT and pathology）, were randomly into two groups, OVC group： a new triple therapy with l-week of Ome plus levofloxacin and clarithromycin, the control group： quadruple therapy with l-week of Ome plus bismuth potassium citrate, amoxicillin and metronidazole （OBAM.）, then two groups are received therapy with 4-week of Ome. Compared with two groups for ulcer healing, H pylori eradication and between the ulcer healing and H pylori reinfection eradication in DU and side effects of drugs. Results Fifty-one Patients are received therapy and followed up. The eradication rates of H pylori reinfection were 92.3%（24/26） and 84.0%（21/25） （P=0.627）, respectively. The ulcer healing rates were 96.2%（25/26） and 92.0%（23/25） in OVC group and OBAM group, respectively （P〉0.05）. There was no significant difference of the side effects of OV group 11.5%（3/26） and OAM group 32.0%（8/25）（P=0.151）. The ulcer healing rates were 100.0% and 72.7% respectively for H pylori eradication and failure of H pylori eradication group in patients （P〈0.001）. Conclusions The new triple therapy（OVC） was efficacy, it will be the first program and remedy treatment selected for H pylori reinfection or H pylori-infected patients after failure of other therapies.
出处
《海南医学》
CAS
2007年第12期1-3,共3页
Hainan Medical Journal
